ZFIN ID: ZDB-FIG-180928-6
Ai et al., 2018 - Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway. Oncotarget   9:31958-31970 Full text @ Oncotarget
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Long-pec

Fig. 1

Effects of Ponatinib on vascular development of zebrafish larvae. (A) Fluorescent images of ISV and SIV in the zebrafish embryos incubated with 0.1% DMSO (Ctrl: vehicle-control), VRI (5 μM), and Ponatinib (1, 3 and 10 μM) for 48 h. VRI was used as the positive control. Red arrow: normal ISV. (B) Number of normal ISV with full-length formation. (C) Quantification of SIV area as a percentage of the control group. The total SIV area was determined by using the NIH image J program. (D) Formation of selected ISV (NO. 4, 7, and 10). All values are presented as means ± SD (n = 12). *P < 0.05 vs. control group, and ***P < 0.005 vs. control group.

Gene Expression Details No data available
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
y1Tg chemical treatment by environment: ponatinib Long-pec angiogenesis disrupted, abnormal
Long-pec intersegmental vessel decreased length, abnormal
Long-pec intersegmental vessel decreased size, abnormal
Long-pec subintestinal vein aplastic, abnormal
Long-pec subintestinal vein decreased size, abnormal
y1Tg chemical treatment by environment: vascular endothelial growth factor receptor antagonist Long-pec angiogenesis disrupted, abnormal
Long-pec subintestinal vein aplastic, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Oncotarget for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Oncotarget